University Hospital of Heraklion_Investigational site number: 3000001
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mengel, Eugen
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26
STARLIGHT, NCT04573023 / 2020-003200-14: A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II

Recruiting
3
80
Europe, US, RoW
JR-141, Idursulfase, JR-141 or Idursulfase
JCR Pharmaceuticals Co., Ltd., JCR Pharmaceuticals Co., Ltd.
Mucopolysaccharidosis II
01/26
01/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT05487599: A Clinical Trial of PR001 (LY3884961) in Patients with Peripheral Manifestations of Gaucher Disease (PROCEED)

Recruiting
1/2
15
Europe, US
LY3884961
Prevail Therapeutics, Eli Lilly and Company
Gaucher Disease, Gaucher Disease, Type 1
10/30
10/30
GALILEO-1, NCT05324943 / 2020-005032-30: A Gene Therapy Study in Patients With Gaucher Disease Type 1

Active, not recruiting
1
18
Europe, US, RoW
FLT201
Freeline Therapeutics, Freeline Therapeutics Limited
Gaucher Disease, Type 1
12/24
01/25
NCT04624789: Registry Gangliosidoses

Recruiting
N/A
40
Europe
SphinCS Lyso Gemeinnutzige UG (Haftungsbeschrankt)
Gangliosidoses, GM1 Gangliosidosis, Morquio B Disease, Sialidosis, Galactosialidosis, Gm2-Gangliosidosis, Variant B1, Tay-Sachs Disease, Sandhoff Disease, GM2 Activator Deficiency
06/20
06/25
Stylianou, Konstantinos
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26
ZHANG, Shanting
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26
Kiriakidi, Konstantina
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26
Spilia, Maria
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26

Download Options